Noida, UP -- (SBWire) -- 11/06/2014 --According to a new research report by RNCOS entitled, “Asia Pacific NIPT Market Outlook 2018”, Australia represents a market with incredible possibilities for growth. In an otherwise weakening market of medical devices, NIPT has emerged as a niche sector with immense growth forecasts. It is estimated that the market, which has recently showcased the entry of six players, is expected to grow at a prolific CAGR during 2013-2018.
The major driver for this growth is the recognition of these tests among the high risk pregnant women in Australia. Our study reveals that the popularity of NIPT tests in Australia is so high that even when the tests were not officially launched in the country, women at high risk of having a baby with chromosomal abnormality were making efforts to get themselves tested from players based in the US. Around 0.17 Million women aged above 30 in Australia gave birth in 2013 and this figure is not expected to change much by 2018. Of these, around 70,000 women fall under the high risk group of 35 years and above. These women represent the consumers that are most likely to buy a NIPT test during pregnancy.
Presently, all the companies follow a similar business model in which they have formed alliances with Australia based pathology labs. These labs collect the blood sample and ship it to the player’s base country, where the sample is tested in the lab. Once the results are generated, they are sent back to the pathology lab that communicates it to the patient. The whole process takes around 14 days. The test costs vary between US$ 700 - US$ 1,500. Since these costs are not covered under insurance, they are borne out-of-pocket by patients. Under such a scenario, companies that realign their operations, such that the tests are conducted in the country itself, will gain the first mover’s advantage. Such companies will be able to deliver the test results faster and at a more competitive price, skewing the consumer’s preference in their favor.
The report provides an in-depth analysis of the current market scenario and expected outlook by 2018. Regions covered in the report include Australia, India, Japan and China. Each region’s data coverage include the number of births, analysis of the potential patient population that will form the customer base for NIPT tests, potential market, market size, forecasts, competitive landscape and regulatory scenario. The report is an outcome of the in-depth analysis of insights generated through interviews with industry leaders and regulatory experts. All the data has been collated through various sources to present the most authentic and impartial picture. It is a must buy for any player that wishes to enter the highly lucrative APAC NIPT market.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM714.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
About RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.
Australia NIPT Market to Expand at a Prolific CAGR
Launch of NIPT tests in a greatly underpenetrated market, representing more than 60,000 high risk pregnancies, has created an unprecedented demand for these tests in Australia, says RNCOS.